Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Kjell Oberg"'
Publikováno v:
Endocrine Connections, Vol 10, Iss 1, Pp 110-123 (2021)
Introduction: The absence of a reliable, universal biomarker is a significant limitation in neuroendocrine neoplasia (NEN) management. We prospectively evaluated two CgA assays, (NEOLISA, EuroDiagnostica) and (CgA ELISA, Demeditec Diagnostics (DD)) a
Externí odkaz:
https://doaj.org/article/ea405e1cc2df4216ac15ee7f2b86ef58
Autor:
Anna Malczewska, Magdalena Witkowska, Karolina Makulik, Agnes Bocian, Agata Walter, Joanna Pilch-Kowalczyk, Wojciech Zajęcki, Lisa Bodei, Kjell Oberg, Beata Kos-Kudła
Publikováno v:
Endocrine Connections, Vol 8, Iss 4, Pp 442-453 (2019)
Introduction: Current monoanalyte biomarkers are ineffective in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). NETest, a novel multianalyte signature, provides molecular information relevant to disease biology. Aim(s): Independently validat
Externí odkaz:
https://doaj.org/article/18f338e04dc146a1927805565379fc97
Autor:
Kjell Oberg, Eric Krenning, Anders Sundin, Lisa Bodei, Mark Kidd, Margot Tesselaar, Valentina Ambrosini, Richard P Baum, Matthew Kulke, Marianne Pavel, Jaroslaw Cwikla, Ignat Drozdov, Massimo Falconi, Nicola Fazio, Andrea Frilling, Robert Jensen, Klaus Koopmans, Tiny Korse, Dik Kwekkeboom, Helmut Maecke, Giovanni Paganelli, Ramon Salazar, Stefano Severi, Jonathan Strosberg, Vikas Prasad, Aldo Scarpa, Ashley Grossman, Annemeik Walenkamp, Mauro Cives, Irene Virgolini, Andreas Kjaer, Irvin M Modlin
Publikováno v:
Endocrine Connections, Vol 5, Iss 5, Pp 174-187 (2016)
The complexity of the clinical management of neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in currently available imaging modalities reflect difficulties
Externí odkaz:
https://doaj.org/article/5d8a8bed100240668fb5e3ecc362659c
Autor:
Justyna Leja, Berith Nilsson, Di Yu, Elisabet Gustafson, Göran Akerström, Kjell Oberg, Valeria Giandomenico, Magnus Essand
Publikováno v:
PLoS ONE, Vol 5, Iss 1, p e8916 (2010)
BACKGROUND: We have previously developed an oncolytic serotype 5 adenovirus (Ad5) with chromogranin-A (CgA) promoter-controlled E1A expression, Ad[CgA-E1A], with the intention to treat neuroendocrine tumors, including carcinoids. Since carcinoids ten
Externí odkaz:
https://doaj.org/article/39dcd38f29aa4004ad14401aa9da8787
Autor:
Andrew Hendifar, Jonathan R. Strosberg, Beth Chasen, Edward M. Wolin, Thomas Thevenet, Philippe Ruszniewski, Eric Krenning, Martyn Caplin, Pamela L. Kunz, Richard P. Baum, T. Hobday, Maribel Lopera Sierra, Ines Margalet, Matthew H. Kulke, Kjell Oberg, David L. Bushnell
Publikováno v:
Journal of Clinical Oncology, 36(25), 2578-+. American Society of Clinical Oncology
Purpose Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in health-related QoL. Methods The NETTER-1 trial is an internationa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea69518a5ea6eed8afffb746722fc12d
https://doi.org/10.1200/jco.2018.78.5865
https://doi.org/10.1200/jco.2018.78.5865
Autor:
Kjell Oberg
Publikováno v:
Nature Reviews Endocrinology. 9:70-72
Neuroendocrine tumours are a heterogeneous group of neoplasms with various clinical presentations, growth rates and responses to available therapies. Studies published in 2012 have provided insights into tumour-cell signalling that will increase our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9087fa77d3e4cb317ccf17a275e6b1a9
https://doi.org/10.1038/nrendo.2012.250
https://doi.org/10.1038/nrendo.2012.250
Publikováno v:
Regulatory Peptides. 117:219-227
The primary structure of human chromogranin A (CgA) not only contains 10 pairs of basic amino acids, which are potential cleavage sites for specific endogenous proteases, but also other sites in the molecule can be subjected to cleavage. Several CgA-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61491e951ff2224d487c94b106e40ea1
https://doi.org/10.1016/j.regpep.2003.10.023
https://doi.org/10.1016/j.regpep.2003.10.023
Autor:
E. P. Krenning, Martyn Caplin, P. Ruszniewsk, Andrew Eugene Hendifar, Beth Chasen, M. Lopera Sierra, Kjell Oberg, Edward M. Wolin, Dirk Jan Kwekkeboom, T. Hobday, J. Strosberg, Matthew H. Kulke, Erik Mittra, Richard P. Baum, David L. Bushnell
Publikováno v:
Radiotherapy and Oncology. 119:S274-S275
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c53314f9c88ba72c6bb7b196a1f5d221
https://doi.org/10.1016/s0167-8140(16)31820-5
https://doi.org/10.1016/s0167-8140(16)31820-5
Autor:
Juan R. Lopez-Egido, Erik Bongcam-Rudloff, T. Kjell Oberg, Janet L. Cunningham, Mikael Berg, Anders E. Gobl
Publikováno v:
Experimental Cell Research. 278:175-183
Recently the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor gene was cloned. Its protein product, called menin, has been shown to associate with the AP1 transcription factor JunD and to repress JunD-mediated transcription. However, littl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9938f37ed33924258c70f654c7e244c
https://doi.org/10.1006/excr.2002.5575
https://doi.org/10.1006/excr.2002.5575
Autor:
Eva Tiensuu Janson, Kjell Oberg
Publikováno v:
Current Pharmaceutical Design. 5:693-705
Somatostatin is a tetradeca peptide hormone produced by many different endocrine cells throughout the body. It is also present in both the central and peripheral nervous system. The peptide has many different moods of action including inhibition of h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edea840390ac43d12444eeb3e6608d25
https://doi.org/10.2174/1381612805666230111195846
https://doi.org/10.2174/1381612805666230111195846